Bristol Myers Squibb (BMY) Cash & Equivalents (2009 - 2026)

Bristol Myers Squibb (BMY) has 18 years of Cash & Equivalents data on file, last reported at $9.6 billion in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $9.6 billion, down 11.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.6 billion (down 11.96% YoY), and the FY2025 annual result was $10.2 billion, down 1.32% from the prior year.
• Cash & Equivalents fell to $9.6 billion in Q1 2026 per BMY's latest filing, from $10.2 billion in the prior quarter.
• Over five years, Cash & Equivalents peaked at $15.7 billion in Q3 2025 and troughed at $6.3 billion in Q2 2024.
• A 5-year average of $10.0 billion and a median of $9.6 billion in 2026 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents slumped 42.88% in 2022, then jumped 100.21% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $9.1 billion in 2022, then rose by 25.66% to $11.5 billion in 2023, then declined by 9.75% to $10.3 billion in 2024, then slipped by 1.32% to $10.2 billion in 2025, then declined by 6.22% to $9.6 billion in 2026.
• Business Quant data shows BMY's Cash & Equivalents at $9.6 billion in Q1 2026, $10.2 billion in Q4 2025, and $15.7 billion in Q3 2025.